Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Bought by Versant Capital Management Inc

Versant Capital Management Inc grew its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 56.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 967 shares of the specialty pharmaceutical company’s stock after buying an additional 350 shares during the period. Versant Capital Management Inc’s holdings in Jazz Pharmaceuticals were worth $119,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in JAZZ. Commonwealth Equity Services LLC increased its stake in Jazz Pharmaceuticals by 2.8% during the second quarter. Commonwealth Equity Services LLC now owns 13,522 shares of the specialty pharmaceutical company’s stock worth $1,443,000 after acquiring an additional 364 shares during the last quarter. Natixis Advisors LLC increased its position in shares of Jazz Pharmaceuticals by 10.7% during the 2nd quarter. Natixis Advisors LLC now owns 21,231 shares of the specialty pharmaceutical company’s stock worth $2,266,000 after purchasing an additional 2,054 shares during the last quarter. Victory Capital Management Inc. raised its holdings in Jazz Pharmaceuticals by 42.7% in the 2nd quarter. Victory Capital Management Inc. now owns 205,492 shares of the specialty pharmaceutical company’s stock valued at $21,932,000 after buying an additional 61,458 shares during the period. Arizona State Retirement System lifted its position in Jazz Pharmaceuticals by 0.8% in the second quarter. Arizona State Retirement System now owns 16,580 shares of the specialty pharmaceutical company’s stock valued at $1,770,000 after buying an additional 130 shares during the last quarter. Finally, Foundry Partners LLC purchased a new position in Jazz Pharmaceuticals during the second quarter worth about $323,000. Institutional investors and hedge funds own 89.14% of the company’s stock.

Insiders Place Their Bets

In related news, CEO Bruce C. Cozadd sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $110.84, for a total transaction of $110,840.00. Following the transaction, the chief executive officer now owns 428,976 shares in the company, valued at $47,547,699.84. This trade represents a 0.23 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Neena M. Patil sold 3,700 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $123.41, for a total value of $456,617.00. Following the transaction, the executive vice president now directly owns 33,048 shares in the company, valued at approximately $4,078,453.68. This trade represents a 10.07 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 6,753 shares of company stock valued at $816,289. 4.20% of the stock is currently owned by insiders.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ JAZZ opened at $120.56 on Friday. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The stock’s 50-day simple moving average is $121.03 and its 200-day simple moving average is $113.68. The firm has a market capitalization of $7.29 billion, a PE ratio of 16.98, a price-to-earnings-growth ratio of 1.04 and a beta of 0.56. Jazz Pharmaceuticals plc has a fifty-two week low of $99.06 and a fifty-two week high of $134.17.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Piper Sandler reaffirmed an “overweight” rating and issued a $163.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. Robert W. Baird boosted their price target on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a research note on Monday, November 18th. Needham & Company LLC restated a “buy” rating and issued a $207.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, December 12th. HC Wainwright reiterated a “buy” rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a report on Friday, November 22nd. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $140.00 price target on shares of Jazz Pharmaceuticals in a research note on Monday, September 9th. Two research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $177.00.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.